Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 15, 2011

Premium

Jeff Boyd will serve as executive director of the new Cancer Genome Institute at Fox Chase Cancer Center in Philadelphia and Dietrich Stephan will serve as its chief scientific officer, when the institute launches in the fall (see story, same issue).

Boyd is the vice president of molecular medicine at Fox Chase, as well as the Robert C. Young, MD, chair in cancer research. He has previously been the director of the Curtis and Elizabeth Anderson Cancer Institute; vice president of oncology and research at the Memorial University Medical Center in Savannah, Ga.; professor of medicine, surgery, obstetrics, and gynecology at the Mercer University School of Medicine; and the assistant dean of research at Mercer University. Additionally, he held a variety of leadership roles at Memorial Sloan Kettering Cancer Center in New York, including as the director of the gynecology and breast research laboratory, and director of the diagnostic molecular genetics laboratory.

Stephan is founder and CEO of the Ignite Inova Institute. He has founded a number of companies including Navigenics, Amnestix, and Aeuon. He has also served as a senior investigator and founding chairman of the department of neurogenomics at the Translational Genomics Research Institute, and as the deputy director of discovery research at TGen. He has held faculty appointments at Johns Hopkins University, George Washington University, and the University of Arizona. He holds a BS in biology/biochemistry from Carnegie Mellon University and a PhD in human molecular genetics from the University of Pittsburgh.


GenomeQuest has appointed Gerry Higgins to healthcare innovation officer, a new position. Higgins will focus on applying the company's proprietary bioinformatics technology to help partners develop whole-genome and multi-gene diagnostics. Previously, Higgins served as vice president for Hoffmann-La Roche Pharmaceuticals, director of clinical informatics and chief innovation officer for MedStar Health, and he also founded the start-up biomedical informatics company SimQuest.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.